Matthias Drosten

3.2k total citations · 1 hit paper
43 papers, 2.0k citations indexed

About

Matthias Drosten is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Matthias Drosten has authored 43 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 21 papers in Oncology and 10 papers in Cell Biology. Recurrent topics in Matthias Drosten's work include Protein Kinase Regulation and GTPase Signaling (12 papers), Cancer-related Molecular Pathways (12 papers) and Melanoma and MAPK Pathways (9 papers). Matthias Drosten is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (12 papers), Cancer-related Molecular Pathways (12 papers) and Melanoma and MAPK Pathways (9 papers). Matthias Drosten collaborates with scholars based in Spain, Germany and United States. Matthias Drosten's co-authors include Mariano Barbacid, Brigitte M. Pützer, Carmen G. Lechuga, Carmen Guerra, Eleanor Y. M. Sum, Lucía Simón-Carrasco, Eugenio Santos, Jelena Urosevic, Luis Miguel Pedrero Esteban and Esther Castellano and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Genes & Development.

In The Last Decade

Matthias Drosten

43 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting the MAPK Pathway in KRAS-Driven Tumors

2020 330 citations Matthias Drosten, Mariano Barbacid Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthias Drosten Spain	22	1.4k	777	301	291	261	43	2.0k
Daniela Califano Italy	29	1.6k 1.1×	964 1.2×	229 0.8×	577 2.0×	211 0.8×	62	2.6k
Qunsheng Ji China	25	1.5k 1.1×	686 0.9×	189 0.6×	560 1.9×	538 2.1×	50	2.5k
Ensar Halilovic United States	19	1.8k 1.2×	977 1.3×	336 1.1×	256 0.9×	375 1.4×	33	2.3k
Nila U. Parikh United States	26	1.5k 1.0×	1.2k 1.6×	272 0.9×	522 1.8×	314 1.2×	39	2.5k
Sohye Kang United States	16	1.9k 1.4×	695 0.9×	300 1.0×	353 1.2×	379 1.5×	18	2.4k
Yasir H. Ibrahim United States	12	1.1k 0.8×	828 1.1×	126 0.4×	249 0.9×	305 1.2×	22	1.6k
Thomas Hattier United States	6	2.1k 1.5×	488 0.6×	359 1.2×	390 1.3×	227 0.9×	7	2.6k
Ka Yin Kwong United States	14	1.7k 1.2×	1.2k 1.5×	290 1.0×	353 1.2×	310 1.2×	17	2.7k
Stefanie S. Schalm United States	13	1.5k 1.0×	428 0.6×	160 0.5×	309 1.1×	387 1.5×	19	2.0k
Bárbara Sousa Portugal	19	841 0.6×	550 0.7×	231 0.8×	493 1.7×	185 0.7×	43	1.4k

Countries citing papers authored by Matthias Drosten

Since Specialization

Citations

This map shows the geographic impact of Matthias Drosten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Drosten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Drosten more than expected).

Fields of papers citing papers by Matthias Drosten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Drosten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Drosten. The network helps show where Matthias Drosten may publish in the future.

Co-authorship network of co-authors of Matthias Drosten

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias Drosten. A scholar is included among the top collaborators of Matthias Drosten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias Drosten. Matthias Drosten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hernández-Porras, Isabel, Lucía Simón-Carrasco, Matthias Drosten, et al.. (2025). Systemic Kras ablation disrupts myeloid cell homeostasis in adult mice. Proceedings of the National Academy of Sciences. 122(34). e2512404122–e2512404122. 2 indexed citations

Fernández‐Pisonero, Isabel, L. Francisco Lorenzo‐Martín, Matthias Drosten, et al.. (2025). Active R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins. Oncogene. 44(24). 1905–1921. 1 indexed citations

Drosten, Matthias & Mariano Barbacid. (2025). The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies. Molecular Oncology. 19(11). 2991–2995. 1 indexed citations

Fernández‐Rodríguez, Ana, Coral Fustero‐Torre, Elena Piñeiro-Yáñez, et al.. (2024). Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors. Proceedings of the National Academy of Sciences. 121(36). e2402913121–e2402913121. 9 indexed citations

Drosten, Matthias, et al.. (2024). HRS-4642: The next piece of the puzzle to keep KRAS in check. Cancer Cell. 42(7). 1157–1159. 4 indexed citations

Drosten, Matthias & Mariano Barbacid. (2022). KRAS inhibitors: going noncovalent. Molecular Oncology. 16(22). 3911–3915. 9 indexed citations

Jacob, Harrys K.C., Sara García‐Alonso, Carmen G. Lechuga, et al.. (2022). KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. Molecular Oncology. 16(17). 3066–3081. 22 indexed citations

Drosten, Matthias & Mariano Barbacid. (2021). Targeting KRAS mutant lung cancer: light at the end of the tunnel. Molecular Oncology. 16(5). 1057–1071. 25 indexed citations

Lechuga, Carmen G., Eduardo Zarzuela, Ruth Álvarez, et al.. (2021). KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. Proceedings of the National Academy of Sciences. 118(30). 12 indexed citations

10.

Real, Sebastián, et al.. (2020). Requirement for epithelial p38α in KRAS-driven lung tumor progression. Proceedings of the National Academy of Sciences. 117(5). 2588–2596. 18 indexed citations

11.

Esteban-Burgos, Laura, Haiyun Wang, Jie Zheng, et al.. (2020). Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Proceedings of the National Academy of Sciences. 117(39). 24415–24426. 15 indexed citations

12.

Drosten, Matthias & Mariano Barbacid. (2020). Targeting the MAPK Pathway in KRAS-Driven Tumors. Cancer Cell. 37(4). 543–550. 330 indexed citations breakdown →

13.

Gao, Yijun, Matthew T. Chang, Daniel J. McKay, et al.. (2018). Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discovery. 8(5). 648–661. 87 indexed citations

14.

Simón-Carrasco, Lucía, Gerardo Jiménez, Mariano Barbacid, & Matthias Drosten. (2018). The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle. 17(6). 702–711. 35 indexed citations

15.

Simón-Carrasco, Lucía, Osvaldo Graña‐Castro, Harrys K.C. Jacob, et al.. (2017). Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. Genes & Development. 31(14). 1456–1468. 38 indexed citations

16.

Simón-Carrasco, Lucía, Leiore Ajuria, Núria Samper, et al.. (2017). A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. PLoS Genetics. 13(3). e1006622–e1006622. 45 indexed citations

17.

Yao, Zhan, Rona Yaeger, Vanessa Rodrik-Outmezguine, et al.. (2017). Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 548(7666). 234–238. 349 indexed citations

18.

Drosten, Matthias, Lucía Simón-Carrasco, Isabel Hernández-Porras, et al.. (2016). H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences. Cancer Research. 77(3). 707–718. 19 indexed citations

19.

Urosevic, Jelena, Eleanor Y. M. Sum, Victoria Moneo, et al.. (2009). Using cells devoid of RAS proteins as tools for drug discovery. Molecular Carcinogenesis. 48(11). 1038–1047. 7 indexed citations

20.

Drosten, Matthias, Gero Hilken, Michelle Bockmann, et al.. (2004). Role of MEN2A-Derived RET in Maintenance and Proliferation of Medullary Thyroid Carcinoma. JNCI Journal of the National Cancer Institute. 96(16). 1231–1239. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact